Lilly Disappoints Street, But Stays Its Course
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly & Co. failed to meet the Street’s expectations on Jan. 5 when it held a guidance call with analysts, largely due to the rapid erosion of its newly genericized antipsychotic Zyprexa.